CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- 8-K Event Executive or director change · Shareholder vote results
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale Chief Development Officer sold 12,000 shares at an average $12.31 ($147,729)
- 144 Insider Sale of Securities
- 8-K Event Regulation FD disclosure · Other events
- 4 Open-market sale President and CEO sold 707 shares at $9.15 ($6,469)
- 4 Open-market sale Chief Development Officer sold 239 shares at $8.76 ($2,094)
- 4 Open-market sale Chief Medical Officer sold 394 shares at $8.76 ($3,451)
- 4 Open-market sale Chief Legal Officer sold 291 shares at $8.76 ($2,549)
- 4 Open-market sale Chief Financial Officer sold 399 shares at $8.76 ($3,495)
- EFFECT Other Notice of Effectiveness
- 4 Open-market sale Chief Development Officer sold 193 shares at $8.78 ($1,695)
- 4 Open-market sale Chief Financial Officer sold 347 shares at $8.78 ($3,047)
- CORRESP Other Correspondence Between Filers and SEC Staff
- S-3/A Offering Registration Statement
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
Page 13 of 24 · 471 filings